Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | FDPS | P14324 | 11/20 | 0.31 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27564774 | 0.88 | KMT2A (0.35) | MEN1CYP1A2KMT2ASOAT1FAAH | |
| SCHEMBL2721706 | 0.81 | AKR1B1 (0.48) | MEN1CYP1A2KMT2AALDH1A1THRB | |
| SCHEMBL27654154 | 0.79 | AKR1B1 (0.46) | MEN1CYP1A2KMT2AALDH1A1THRB | |
| SCHEMBL7634805 | 0.78 | HMGCR (0.47) | MEN1CYP1A2KMT2ASOAT1FAAH | |
| SCHEMBL21015504 | 0.76 | FFAR1 (0.38) | MEN1CYP1A2KMT2ASOAT1FAAH | |
| SCHEMBL20198070 | 0.76 | MEN1 (0.38) | MEN1CYP1A2KMT2ASOAT1FAAH | |
| SCHEMBL27939660 | 0.76 | SOAT1 (0.57) | MEN1CYP1A2KMT2ASOAT1FAAH | |
| SCHEMBL28520533 | 0.76 | SOAT1 (0.57) | MEN1CYP1A2KMT2ASOAT1FAAH | |
| SCHEMBL14321929 | 0.75 | ALDH1A1 (0.45) | MEN1CYP1A2KMT2ASOAT1FAAH | |
| SCHEMBL4147412 | 0.74 | CYP4F2 (0.37) | MEN1CYP1A2KMT2ASOAT1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035274-A1 | Process for producing simvastatin and/or its derivatives | DALEN FRANS VAN (NL) | 2002-03-21 | — | — | US | disclosed |
| US-6271398-B1 | INVOLVES THE USE OF HYDROXYL PROTECTED INTERMEDIATES THAT ALLOW FOR DIRECT ALKYLATION OF THE BUTYRATE SIDE CHAIN FOLLOWED BY DEPROTECTION AND REFORMATION OF THE LACTONE RING. | SYNTHON BV (NL) | 2001-08-07 | — | — | US | disclosed |
| WO-2001034590-A1 | PROCESS FOR MANUFACTURING SIMVASTATIN AND THE NOVEL INTERMEDIATES | BIOCON INDIA LIMITED (IN) | 2001-05-17 | — | — | WO | disclosed |
| US-6100407-A | Process for producing simvastatin and/or its derivatives | SYTHON, B.V. (NL) | 2000-08-08 | — | — | US | disclosed |
| WO-1995013283-A1 | PROCESS FOR PRODUCING SIMVASTATIN AND ANALOGS THEREOF | APOTEX INC. (CA) | 1995-05-18 | — | — | WO | disclosed |
| US-5393893-A | Alkylation of the 2-methylbutyryloxy side chain of boranediyl derivative of lovastatin yields 2-alkyl-2-methylbutyryloxy derivative, simplification, efficiency, nontoxic | APOTEX, INC. (CA) | 1995-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035274-A1 | Process for producing simvastatin and/or its derivatives | HMGCR, HSD17B12, CYP3A7 | MEN1 3721/4885CYP1A2 117/4885KMT2A 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.